Skip to main content
Article thumbnail
Location of Repository

Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers

By Ellen R. Copson, Helen E. White, Jeremy P. Blaydes, David O. Robinson, Peter W. Johnson and Diana M. Eccles

Abstract

Background<br/><br/>The MDM2 gene encodes a negative regulator of the p53 tumour suppressor protein. A single nucleotide polymorphism (SNP) in the MDM2 promoter (a T to G exchange at nucleotide 309) has been reported to produce accelerated tumour formation in individuals with inherited p53 mutations. We have investigated the effect of the MDM2 SNP309 on clinical outcome in a cohort of patients with germline mutations of BRCA1.<br/><br/>Methods<br/><br/>Genomic DNA was obtained for 102 healthy controls and 116 patients with established pathogenic mutations of BRCA1 and Pyrosequencing technology™ was used to determine the genotype at the MDM2 SNP309 locus.<br/><br/>Results<br/><br/>The polymorphism was present in 52.9% of the controls (G/T in 37.3% and G/G in 15.6%) and 58.6% of the BRCA1 mutation carriers (47.4% G/T and 11.2% G/G). Incidence of malignancy in female BRCA1 carriers was not significantly higher in SNP309 carriers than in wildtype (T/T) individuals (72.7% vs. 75.6%, p = 1.00). Mean age of diagnosis of first breast cancer was 41.2 years in the SNP309 G/G genotype carriers, 38.6 years in those with the SNP309 G/T genotype and 39.0 years in wildtype subjects (p = 0.80).<br/><br/>Conclusion<br/><br/>We found no evidence that the MDM2 SNP309 accelerates tumour development in carriers of known pathogenic germline mutations of BRCA1

Topics: RC0254, QH426
Year: 2006
OAI identifier: oai:eprints.soton.ac.uk:40669
Provided by: e-Prints Soton

Suggested articles

Citations

  1. (2005). A: A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res
  2. (2005). Aaltonem L-M, Aaltonen AA: The MDM2 promoter polymorphism SNP309T>G and the risk of uterine leiomyosarcoma, colorectal cancer and squamous cell carcinoma of the head and neck.
  3. (2004). AJ: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumour suppressor pathway and accelerates tumour formation in humans. Cell
  4. (1999). AJ: Regulation of the p53 protein by the MDM2 oncoprotein – thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res
  5. (1996). Albitar M: Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res Treat
  6. (1999). BH: Mammary tumour formation in p53-and BRCA1 deficient mice. Cell Growth Differ
  7. (2004). BL: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE study group.
  8. (1996). Brca1 deficiency results in early embryonic lethality characterised by neuroepitheilial. Nat Genet
  9. (1997). CA: Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev
  10. (2005). Choong DYH: No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Letts
  11. (2005). CM: MDM2 binds to nbs1 at sites of DNA damage and regulates double strand break repair.
  12. (2002). DF: The pathology of familial breast cancer: Predictive value of immunohistochemical markers oestrogen receptor,
  13. (1998). El-Deiry WS: BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene
  14. (1994). Goldgar DE: Risk of cancer in BRCA1 mutation carriers. Lancet
  15. (1997). Gusterson BA: p53 mutations in BRCA1-associated familial breast cancer. Lancet
  16. (2000). Hakem R: Brcal required for T cell lineage development but not TCR loci rearrangement. Nature Immunol
  17. (1995). IG: MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
  18. (1999). Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers.
  19. (2000). Insight into the functions of BRCA1 and BRCA2. Trends Genet
  20. (1997). MA: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 mutations among Ashkenazi Jews.
  21. (2005). Phenotypic characterisation of BRCA1 and BRCA2 tumours based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat
  22. (2002). Prevention and Observation of Surgical End Points Study Group P: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
  23. (1996). The tumour suppressor gene Brca1 is required for early embryonic cellular proliferation in the mouse. Cell
  24. (1997). TW: Partial rescue of Brca1 early embryonic lethality by p53 or p21 null mutation. Nature Genetics
  25. (1992). Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.